Systematic review and meta-analysis of randomized controlled trials: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. ABSTRACT Background: A lack of reliable treatments for abdominal pain-related functional gastrointestinal disorders (FGD) prompts interest in new therapies. Aim: To systematically evaluate the effect of Lactobacillus rhamnosus GG (LGG) for treating abdominal pain-related FGD in children. Methods: MEDLINE, EMBASE, CINAHL, the Cochrane Library, trial registries, and proceedings of major meetings were searched for randomized controlled trials (RCTs) evaluating LGG supplementation in children with abdominal pain-related FGD based on the Rome II or Rome III criteria. Risk of bias was assessed for generation of the allocation sequence, allocation concealment, blinding, and followup.
Recently, probiotics, defined as 'live microorganisms which when administered in adequate amounts confer a health benefit on the host' 3 Previously, 4 meta-analyses 5 6 7 8 and 1 systematic review 9 evaluated the effects of probiotics for the treatment of IBS, primarily in the adult population, and reached slightly different conclusions. For adults, despite the equivocal results, the American College of Gastroenterology recently concluded that 'in single organism studies, lactobacilli do not appear effective; bifidobacteria and certain combinations of probiotics demonstrate some efficacy.' 10 Regarding the pediatric population, a Cochrane systematic review 11 (search date: December 2006) concluded that there is no evidence that lactobacillus supplementation is effective in the management of children with recurrent abdominal pain. New studies 12, 13 have been published since this metaanalysis, prompting interest in re-evaluating the role of probiotics in the management of abdominal pain-related FGD in children. With this systematic review, we aimed to update and synthesize the available randomized controlled compared with placebo or no intervention in children affected by abdominal painrelated FGD. In contrast to previous meta-analyses, whether performed in adults or in children, we focused on a single probiotic microorganism. This is because the beneficial effects of probiotics seem to be strain specific, thus, pooling data on different strains may result in misleading conclusions. The choice of the probiotic
LGG was determined by the fact that it is available and commonly used in many countries, and it has demonstrated efficacy in the treatment of some gastrointestinal conditions in children. 14 15 
METHODS

Criteria for considering studies for this review
All relevant RCTs that compared the effects of LGG supplementation with the effects of placebo or no supplementation for treating abdominal pain-related FGD in children were considered for this review. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Search methods for identification of studies
Selection of studies
We excluded studies if the title and abstract were not relevant; however, we obtained papers for all potentially relevant studies if the abstract contained insufficient information to warrant exclusion. All areas of disagreement were discussed by the researchers in order to achieve a consensus.
Data extraction and management
Data from each study were extracted by all of the reviewers using standardized data extraction forms. The data sought included baseline characteristics of the participants (age, diagnostic criteria), the LGG dose and duration of the intervention, follow-up duration, the nature of the placebo, and all outcome measures with their definitions, as reported by the authors. After extraction, all data were compared in order to minimize the possibility of errors.
Assessment of risk of bias in included studies
The reviewers independently, but without being blinded to the authors or journal, assessed the risk of bias in the studies that met the inclusion criteria. We used the 
Measures of treatment effect
The dichotomous outcomes, the results for individual studies, and pooled statistics are reported as the risk ratio (RR) between the experimental and control groups with 95% confidence intervals (CI). The standardized mean difference (SMD) between the treatment and control groups was selected to represent the difference in continuous outcomes (with 95% CI). For all outcomes, subgroup analyses based on the diagnosis (i.e., IBS, FAP, FD) were performed.
Dealing with missing data
We assessed pooled data using available case analysis, i.e., an analysis in which data are analyzed for every participant for whom the outcome was obtained, rather than intention-to-treat analysis with imputation. 17
Assessment of heterogeneity
Heterogeneity was quantified by 2 and I 2 , which can be interpreted as the percentage of the total variation between studies that is attributable to heterogeneity rather than to chance. A value of 0% indicates no observed heterogeneity, and larger values show increasing heterogeneity. If heterogeneity was not revealed, we present results of only the fixed effects model. If there was substantial heterogeneity (over 50%), all 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 analyses were based on the random effects model if it was still considered appropriate to pool the data.
Data synthesis (Statistical methods)
The data were analyzed using Review Manager (RevMan) [Computer program. 
RESULTS
Included studies
The literature search initially yielded 45 articles, of which 3 RCTs met the inclusion criteria (Figure 1) . 12, 18, 19 All were published in English. These trials randomized a total of 290 patients. Table 1 summarizes the characteristics of the included studies. All 3 studies enrolled patients with IBS, 12, 18, 19 2 RCTs enrolled patients with FAP, 12, 19 and 1 RCT also enrolled children with FD. 19 In all of the studies, the diagnoses were made according to the Rome II criteria. The sample size ranged from 64 to 141 participants.
In all of the studies, LGG was compared with placebo. The daily dose of LGG ranged from 10 9 CFU twice daily 18 to 3 x 10 9 CFU twice daily, 12, 19 and supplementation lasted for 4 weeks 19 , 6 weeks, 18 or 8 weeks 12 . Two RCTs were undertaken in the 2 European countries Poland (one RCT) 19 and Italy (one RCT), 12 and one RCT was conducted in the United States. 18 No heterogeneity for the primary outcome was found (I 2 =0%). For the secondary outcomes, significant heterogeneity (I 2 ≥50%) was found for the overall study population for the frequency of pain (chi 2 =9.15, p=0.002, I 2 =89%) and the intensity of pain (chi 2 =2.21, p=0.14, I 2 =55%). In all cases, the observed statistical heterogeneity was not judged to be clinically relevant (i.e., studies consistently reported results in the same direction with clinically insignificant differences between the studies).
Risk of bias in included trials
However, there were too few studies to adequately determine heterogeneity. 20
Effects of intervention
Primary outcome
All 3 RCTs reported responders to the treatment or treatment success defined as no pain or a decrease in pain intensity (Figure 2) . One RCT 19 found no evidence that LGG supplementation influenced the treatment response in these children.
Secondary outcomes
Frequency of pain
Only for a subgroup of children with IBS, the frequency of pain was reduced in those in the LGG group compared with those in the placebo group (2 RCTs, n=117; SMD - 9 1.04, 95% CI -1.43 to -0.65). For the overall study population, as well as for the subgroups of children with FAP or FD, there were no differences in the frequency of pain between the groups that received placebo or LGG (Figure 3 ).
Intensity/severity of pain
Compared with placebo, the use of LGG was associated with a significant decrease in the perception of pain intensity in the overall study population with abdominal painrelated FGD (2 RCTs, n=240; SMD -0.44, 95% CI -0.82 to -0.05). Similarly, there was a reduction in pain intensity in the subgroup of children with IBS who received LGG compared with placebo (2 RCTs, n=117; SMD -0.60, 95% CI -0.97 to -0.23), but not in children with FAP and FD (Figure 4) .
Adverse effects
The LGG was well tolerated and no adverse effects were reported.
DISCUSSION
Summary of main results
This meta-analysis provides a summary of current knowledge regarding the effects of a single probiotic microorganism, LGG, in children affected by abdominal painrelated FGD. With the limited evidence available, we found that the use of LGG increased the proportion of responders to the treatment (defined as no pain or a decrease in pain intensity) in children with abdominal pain-related FGD, particularly among children with IBS. Additionally, LGG reduced the frequency and intensity of pain, again particularly among children with IBS. Of note, although positive and statistically significant, the effects were clinically modest.
Overall completeness and applicability of evidence
Our search included 3 major databases, with no language restrictions. The searching, extraction of the data, and assessment of the validity of the studies were performed independently by 2 reviewers to decrease the likelihood of reviewer error or bias.
Still, we cannot fully exclude the possibility of publication bias, which is an 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w important threat to the validity of systematic reviews and is difficult to combat except through the registration of all RCTs. We did not perform a statistical test for the detection of publication bias, as we are aware that these tests have very low power in the meta-analysis of only a few trials. 21 One strength of our review, which distinguishes it from other reviews, is that it focuses on only one probiotic microorganism. This is because probiotic supplementation is not a homogeneous intervention. Pooling data from different genera, species, strains, and doses of probiotics may result in misleading conclusions.
Quality of evidence
Any systematic review is only as good as the constituent studies. In general, the included RCTs were of sound methodology with adequate randomization, allocation concealment, blinding, and follow-up. One potential limitation of the review is that it included a small number of trials with a small sample size, particularly when subgroups of patients with specific diagnoses were evaluated. However, to increase power is one of the reasons why a meta-analysis is performed within a systematic review.
In all of the included trials, the probiotic intervention lasted not less than 4 weeks, which is in line with the Rome Foundation document providing guidance for the design of treatment trials in patients with FGD. 22 However, there is a lack of data on the long-term effects of LGG treatment for abdominal pain-related FGD. Only one study 12 analyzed children for 8 weeks after cessation of the therapy.
According to the published recommendations, 22 the primary outcome measure for treatment studies in patients with FGD should be defined as 'adequate relief' or 'satisfactory relief'. However, studies assessing this outcome measure in the pediatric population are lacking. To our knowledge, no outcome measures for FGD are sufficiently validated to be recommended unequivocally for use as the primary outcome measure. 22 The studies included in our review used different scales and different definitions in assessing treatment success and treatment response. While in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 11 2 trials, validated tools (Faces Pain Scale and Visual Analog Scale) were used, the definition of treatment success was subjective. 12, 19 In the remaining study, 18 the investigators used a psychometric scale that was not validated for the pediatric population.
All 3 RCTs were placebo controlled, which is considered an essential requirement for interventional studies of FGD. However, there were differences in the choice of placebo. Two of the 3 RCTs used inulin and maltodextrin as their placebos. 18 19 As these are potential prebiotics, it could have affected the outcome. However, this was not observed in our analysis. Still, the choice of the placebo should be taken into account when designing future studies.
Agreement and disagreement with other studies or reviews
Compared with the previously published Cochrane review, 11 which concluded that there is no evidence that lactobacillus supplementation is effective in the management of children with recurrent abdominal pain, our review focuses on a single probiotic microorganism and also includes recent data. Thus, our results more precisely define the effects of LGG. In adults, as discussed in the Introduction, some meta-analyses 6 7 8 have shown that some probiotics are clinically more effective than placebo in the treatment of irritable bowel syndrome. However, there are no data on
LGG given as a single probiotic.
Implications for practice
The results of our systematic review provide preliminary evidence that LGG may be useful for treating children with abdominal pain-related FGD, particularly in a subgroup of children with IBS. While it is too soon to recommend its routine use in clinical practice, given the lack of effective therapy for abdominal pain-related FGD and the generally good safety profile of LGG in an otherwise healthy population, this therapeutic option could be discussed with patients and/or caregivers. 12 LGG seems to be a good candidate for a large multicenter trial in children with abdominal pain-related FGD, properly categorized into IBS, FAP, and FD. Due to the relapsing nature of the disease and that effects of probiotics may endure only for as long as the organism is administered, the treatment duration and follow-up period after cessation of treatment should allow for the adequate assessment of short-and long-term effects of LGG. There is also a strong need for a standardized, properly validated outcome assessments scale. Due to the fact that the exact mechanism of action of LGG is not known, experimental studies are desirable.
Implications for research
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5
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
4,5
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. 
NA
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
RESULTS
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
6 Fig. 1 Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15).
7
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16] ).
NA
DISCUSSION
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
8,9
Limitations 25 Discuss limitations at study and outcomelevel (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
9,10
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.
11
FUNDING
Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.
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